CAMBRIDGE, MA / ACCESSWIRE / July 5, 2023 / Q-State Biosciences ("Q-State") has been acquired by Exponential Capital Management and rebranded to Quiver Bioscience ("Quiver") as part of the company's continued evolution. The name change reflects a readiness and focus to bring new drugs for neurological disease targets to the clinic leveraging a proprietary platform that delivers unique cellular insights into excitable tissues such as the brain.
Quiver utilizes scalable human disease models, novel AI, and a best-in-world platform to drive therapeutic discovery with the mission of creating transformational medicines for patients living with disorders of the brain. Paul Roma, CEO, ‘After a decade of engineering, we can now test more neurons in an hour than the rest of the world can in years. Our platform fingerprints both targets and drugs at scale, making us the premier discovery partner in advancing medicines from target to the clinic'. The Quiver platform has been built and validated and is now poised to deliver the best possible medicines for patients suffering from disorders of the brain. Quiver is currently deploying its platform to discover therapeutics in areas of critical need such as chronic pain, neurodevelopmental disorders, and neurodegeneration.
About Exponential Capital Management
Exponential Capital Management is a venture fund focused on the intersection between Healthcare and advanced technologies in precision medicine, diagnostics, and patient care. Our firm blends traditional venture investing in early-stage and growth-stage companies with an existing ecosystem for accelerated innovation and market disruption. For more information, please visit https://www.exponentialcap.com.
About Quiver Bioscience
Quiver is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map "Genomic Positioning System" through proprietary engineering and AI/ML approaches. Our approach integrates cutting-edge scalable biology, state-of-the-art technology, and engineering, and learning and surrogate models to identify novel therapeutic targets and the best candidate molecules to deliver new and meaningful therapeutics to patients. For more information, please visit www.quiverbioscience.com.
Quiver Bioscience
+1 617-945-5433
Visit us on social media:
Twitter: https://twitter.com/QuiverBio
LinkedIn: https://www.linkedin.com/company/quiverbioscience/
SOURCE: Quiver Bioscience